Browsing by Author "Bahceci, Aykut"
Now showing items 1-9 of 9
-
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers?
Kacan, Turgut; Babacan, Nalan Akgul; Seker, Metin; Yucel, Birsen; Bahceci, Aykut; Eren, Ayfer Ay; Eren, Mehmet Fuat; Kilickap, Saadettin (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or ... -
Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells
Kacan, Turgut; Altun, Ahmet; Altun, Gulsah Gultekin; Kacan, Selen Baloglu; Sarac, Bulent; Seker, Mehmet Metin; Bahceci, Aykut; Babacan, Nalan (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: Breast cancer evolution and tumor progression are controlled by complex interactions between steroid receptors and growth factor receptor signaling. Aberrant growth factor receptor signaling can augment or ... -
The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG)
Tanriverdi, Ozgur; Menekse, Serkan; Teker, Fatih; Oktay, Esin; Pilanci, Kezban Nur; Gunaldi, Meral; Kocar, Muharrem; Kacan, Turgut; Bahceci, Aykut; Avci, Nilufer; Akman, Tulay; Cokmert, Suna; Yesil-Cinkir, Havva; Yanmaz, Mustafa Teoman (ZERBINIS MEDICAL PUBL, 2016)Purpose: To determine the predictive value of the mean platelet volume (MPV) and the MPV/platelet count ratio on the development of isolated bone metastasis in patients with breast cancer. Methods: A total of 121 previously ... -
Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder
Erdem, Gokmen U.; Dogan, Mutlu; Sakin, Abdullah; Oruc, Zeynep; Yaman, Emel; Cinkir, Havva Yesil; Uysal, Mukremin; Bozkurt, Oktay; Ozturk, Banu; Aytekin, Aydin; Ozcelik, Melike; Bahceci, Aykut; Cakiroglu, Umut; Turhal, Serdar; Sahin, Suleyman; Uncu, Dogan; Zengin, Nurullah (KARGER, 2018)Objectives: The clinicopathological characteristics, treatment modalities, and effects on the prognosis of pure squamous cell carcinoma (SqCC) and adenocarcinoma (AC) were evaluated. Materials and Methods: 86 patients with ... -
The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism
Kacan, Turgut; Yucel, Birsen; Bahar, Seher; Celasun, Gurol; Seker, Mehmet M.; Babacan, Nalan; Bahceci, Aykut; Kacan, Selen B.; Kilickap, Saadettin (AKAD DOKTORLAR YAYINEVI, 2016)Systemic activation of coagulation and fibrinolysis is frequently observed in cancer patients without thrombosis. Recent studies have showed the association between D-Dimer (DD) and metastatic spread and prognosis of cancer. ... -
Prognostic value of serum TIE-2 and vascular endothelial growth factor levels in gastric cancer patients.
Seker, Mehmet Metin; Sancakdar, Enver; Seker, Ayse; Bahceci, Aykut; Kacan, Turgut; Babacan, Nalan (AMER SOC CLINICAL ONCOLOGY, 2014)… -
The prognostic value of UHRF-1 and p53 in gastric cancer
Babacan, Nalan A.; Egilmez, Hatice Reyhan; Yucel, Birsen; Parlak, Ilknur; Seker, Mehmet Metin; Kacan, Turgut; Bahceci, Aykut; Cihan, Sener; Akinci, Bulent; Eriten, Berna; Kilickap, Saadettin (MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2016)Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with ... -
Serum leptin and adiponectin levels and relationship with prognosis in lung cancer.
Seker, Mehmet Matin; Sancakdar, Enver; Nadir, Aydin; Altun, Gulsah; Bahceci, Aykut; Kacan, Turgut; Babacan, Nalan; Kaptanoglu, Mellh (AMER SOC CLINICAL ONCOLOGY, 2014)… -
XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
Duran, Ayse Ocak; Karaca, Halit; Besiroglu, Mehmet; Bayoglu, Ibrahim Vedat; Menekse, Serkan; Yapici, Heves Surmeli; Yazilitas, Dogan; Bahceci, Aykut; Uysal, Mukremin; Sevinc, Alper; Hacibekiroglu, Ilhan; Aksoy, Asude; Tanriverdi, Ozgur; Arpaci, Erkan; Inanc, Mevlude; Dane, Faysal; Ozkan, Metin (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare ...
